Anti-tumor activities of MSCs are the suppression of angiogenesis through the PDGF-PDGFR axis or FAK axis, suppression of tumor cell proliferation through the inhibition of cyclin D or EGFR expression in tumor cells, and sensitization of the GBM tumor to chemotherapy (described in detail in recent reviews by Nowak, Blazej et al. [185] and Adriana Bajetto et al. [187]). The gene discussed is PTK2; the disease is neoplasm.